RYE, N.Y., April 19 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, will present at the Rodman & Renshaw 6(th) Annual Global Healthcare Conference, to be held May 16 -18 in London, the company announced.
CM-AT, one of the first therapies to address the underlying physiology of autism, is based on Dr. Fallon’s research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. Curemark anticipates expanding its research program to examine its science in relation to other neurological conditions such as ADHD.
More than 175 companies focused on areas including autoimmune diseases, cardiovascular diseases, gene therapy and oncology, are scheduled to present at the conference.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
CONTACT: Michelle Manoff, Rubenstein Public Relations, +1-212-843-8051,
mmanoff@rubensteinpr.com; or Dr. Joan Fallon of Curemark LLC,
+1-914-925-3450, joan.fallon@curemark.com
Web site: http://www.curemark.com/
